Literature DB >> 35918332

Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.

Yajun Duan1,2, Ke Gong2, Suowen Xu1, Feng Zhang2, Xianshe Meng2, Jihong Han3,4.   

Abstract

Disturbed cholesterol homeostasis plays critical roles in the development of multiple diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and cancers, particularly the CVD in which the accumulation of lipids (mainly the cholesteryl esters) within macrophage/foam cells underneath the endothelial layer drives the formation of atherosclerotic lesions eventually. More and more studies have shown that lowering cholesterol level, especially low-density lipoprotein cholesterol level, protects cardiovascular system and prevents cardiovascular events effectively. Maintaining cholesterol homeostasis is determined by cholesterol biosynthesis, uptake, efflux, transport, storage, utilization, and/or excretion. All the processes should be precisely controlled by the multiple regulatory pathways. Based on the regulation of cholesterol homeostasis, many interventions have been developed to lower cholesterol by inhibiting cholesterol biosynthesis and uptake or enhancing cholesterol utilization and excretion. Herein, we summarize the historical review and research events, the current understandings of the molecular pathways playing key roles in regulating cholesterol homeostasis, and the cholesterol-lowering interventions in clinics or in preclinical studies as well as new cholesterol-lowering targets and their clinical advances. More importantly, we review and discuss the benefits of those interventions for the treatment of multiple diseases including atherosclerotic cardiovascular diseases, obesity, diabetes, nonalcoholic fatty liver disease, cancer, neurodegenerative diseases, osteoporosis and virus infection.
© 2022. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35918332      PMCID: PMC9344793          DOI: 10.1038/s41392-022-01125-5

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  582 in total

Review 1.  Mechanisms and regulation of cholesterol homeostasis.

Authors:  Jie Luo; Hongyuan Yang; Bao-Liang Song
Journal:  Nat Rev Mol Cell Biol       Date:  2019-12-17       Impact factor: 94.444

2.  FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors.

Authors:  Anna C Calkin; Benjamin T Goult; Li Zhang; Louise Fairall; Cynthia Hong; John W R Schwabe; Peter Tontonoz
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-22       Impact factor: 11.205

Review 3.  Cholesteryl esters in malignancy.

Authors:  Maria R Tosi; Vitaliano Tugnoli
Journal:  Clin Chim Acta       Date:  2005-09       Impact factor: 3.786

4.  Transintestinal and Biliary Cholesterol Secretion Both Contribute to Macrophage Reverse Cholesterol Transport in Rats-Brief Report.

Authors:  Jan Freark de Boer; Marleen Schonewille; Arne Dikkers; Martijn Koehorst; Rick Havinga; Folkert Kuipers; Uwe J F Tietge; Albert K Groen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-02-23       Impact factor: 8.311

5.  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.

Authors: 
Journal:  JAMA       Date:  1984-01-20       Impact factor: 56.272

6.  Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells.

Authors:  Hsiu-Chung Ou; Wen-Jane Lee; I-Te Lee; Tsan-Hung Chiu; Kun-Ling Tsai; Chih-Ying Lin; Wayne Huey-Herng Sheu
Journal:  J Appl Physiol (1985)       Date:  2009-02-19

7.  Lipids and risk of coronary heart disease. The Framingham Study.

Authors:  W P Castelli; K Anderson; P W Wilson; D Levy
Journal:  Ann Epidemiol       Date:  1992 Jan-Mar       Impact factor: 3.797

8.  Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.

Authors:  Kausik K Ray; R Scott Wright; David Kallend; Wolfgang Koenig; Lawrence A Leiter; Frederick J Raal; Jenna A Bisch; Tara Richardson; Mark Jaros; Peter L J Wijngaard; John J P Kastelein
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

9.  Effects of extended-release niacin with laropiprant in high-risk patients.

Authors:  Martin J Landray; Richard Haynes; Jemma C Hopewell; Sarah Parish; Theingi Aung; Joseph Tomson; Karl Wallendszus; Martin Craig; Lixin Jiang; Rory Collins; Jane Armitage
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

10.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.